TJBH — Tengjun Biotechnology Income Statement
0.000.00%
Consumer CyclicalsSpeculativeMicro Cap
Annual income statement for Tengjun Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 150 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 0 | 140 |
Selling / General / Administrative Expenses | |||||
Total Operating Expenses | 0.03 | 0.039 | 0.032 | 0.738 | 134 |
Operating Profit | -0.03 | -0.039 | -0.032 | -0.738 | 16.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.048 | -0.06 | -0.054 | -0.748 | 15.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.048 | -0.06 | -0.054 | -0.748 | 12 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -0.048 | -0.06 | -0.054 | -0.748 | 11.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.048 | -0.06 | -0.054 | -0.748 | 11.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.001 | -0.002 | -0.001 | -0.037 | 0.142 |